International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.
fecal calprotectin
inflammatory bowel disease
measurement
standardization
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
18
01
2021
accepted:
26
02
2021
pubmed:
8
5
2021
medline:
19
1
2022
entrez:
7
5
2021
Statut:
ppublish
Résumé
Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which is frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step of FC measurement can influence the results, leading to misinterpretations and potentially impacting the management of IBD patients. To date, there is high heterogeneity between FC measurements and no current method is universally accepted as a standard. Our aim was to provide clear position statementsabout the pre-analytical and the analytical phases of FC measurement to homogenize FC levels and to minimize variability and risk of misinterpretation through aninternational consensus. Fourteen physicians with expertise in the field of IBD and FC from 11 countries attended a virtual international consensus meeting on July 17th, 2020. A systematic literature was conducted and the literature evidence was shared and discussedamong the participants. Statements were formulated, discussed, and voted. Statements were considered approved if all participants agreed. Nine statements were formulated and approved. Based on the available evidence, quantitative tests should be preferred for measuring FC. Furthermore, FC measurement, if possible, should always be performed with the same method and factors influencing FC levels should be taken into account when interpreting the results. FC has an increasingly important role in the management of patients with IBD. However, large multicenter studies should be conducted to define the reproducibility and to confirm the diagnostic accuracy of the available FC tests. FC concentrations guide clinicians' treatment decisions. Our statements have a relevant impact in daily practice and could be applied in clinical trials to standardize FC measurement.
Sections du résumé
BACKGROUND
Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which is frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step of FC measurement can influence the results, leading to misinterpretations and potentially impacting the management of IBD patients. To date, there is high heterogeneity between FC measurements and no current method is universally accepted as a standard.
AIMS
Our aim was to provide clear position statementsabout the pre-analytical and the analytical phases of FC measurement to homogenize FC levels and to minimize variability and risk of misinterpretation through aninternational consensus.
MATERIALS & METHODS
Fourteen physicians with expertise in the field of IBD and FC from 11 countries attended a virtual international consensus meeting on July 17th, 2020. A systematic literature was conducted and the literature evidence was shared and discussedamong the participants. Statements were formulated, discussed, and voted. Statements were considered approved if all participants agreed.
RESULTS
Nine statements were formulated and approved. Based on the available evidence, quantitative tests should be preferred for measuring FC. Furthermore, FC measurement, if possible, should always be performed with the same method and factors influencing FC levels should be taken into account when interpreting the results.
DISCUSSION
FC has an increasingly important role in the management of patients with IBD. However, large multicenter studies should be conducted to define the reproducibility and to confirm the diagnostic accuracy of the available FC tests.
CONCLUSION
FC concentrations guide clinicians' treatment decisions. Our statements have a relevant impact in daily practice and could be applied in clinical trials to standardize FC measurement.
Identifiants
pubmed: 33961734
doi: 10.1002/ueg2.12069
pmc: PMC8259254
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Types de publication
Consensus Development Conference
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-460Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK042086
Pays : United States
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Références
United European Gastroenterol J. 2014 Feb;2(1):30-7
pubmed: 24918006
United European Gastroenterol J. 2019 May;7(4):496-506
pubmed: 31065367
Gut. 1999 Sep;45(3):362-6
pubmed: 10446103
Scand J Gastroenterol. 2019 Feb;54(2):152-157
pubmed: 30676120
J Crohns Colitis. 2012 Mar;6(2):207-14
pubmed: 22325175
J Crohns Colitis. 2021 Jan 13;15(1):152-161
pubmed: 32392336
Inflamm Bowel Dis. 2020 Jun 18;26(7):1098-1109
pubmed: 31644793
Gastroenterol Hepatol. 2018 Oct;41(8):514-529
pubmed: 30293556
Gastroenterology. 2019 Sep;157(3):859-880
pubmed: 31351880
Scand J Gastroenterol. 2016;51(5):548-55
pubmed: 26634305
Biochem Med (Zagreb). 2019 Feb 15;29(1):010707
pubmed: 30799976
Intest Res. 2019 Apr;17(2):202-209
pubmed: 30541228
Clin Gastroenterol Hepatol. 2020 Feb;18(2):524-525
pubmed: 31937401
Gut. 2000 Oct;47(4):506-13
pubmed: 10986210
Am J Perinatol. 2015 Mar;32(4):337-42
pubmed: 25111039
Am J Clin Pathol. 2019 Aug 1;152(3):392-398
pubmed: 31152542
Clin Lab. 2020 Jul 1;66(7):
pubmed: 32658433
PLoS One. 2019 Apr 18;14(4):e0214751
pubmed: 30998692
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
J Pediatr Gastroenterol Nutr. 2012 Dec;55(6):751-3
pubmed: 22614113
Scand J Gastroenterol. 1992 Sep;27(9):793-8
pubmed: 1411288
Inflamm Bowel Dis. 2014 Nov;20(11):2056-66
pubmed: 25265263
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):926-931
pubmed: 29240011
J Crohns Colitis. 2020 Jun 19;14(5):688-693
pubmed: 31858121
PLoS One. 2019 Dec 2;14(12):e0224895
pubmed: 31790426
Gut. 2016 May;65(5):749-56
pubmed: 26719299
United European Gastroenterol J. 2018 Aug;6(7):1007-1014
pubmed: 30228888
Am J Med. 2008 Dec;121(12):1099-106
pubmed: 19028207
Aliment Pharmacol Ther. 2013 Mar;37(6):613-21
pubmed: 23347334
Pract Lab Med. 2017 Nov 21;10:10-14
pubmed: 29234707
J Clin Lab Anal. 2017 Jul;31(4):
pubmed: 27629827
Ann Clin Biochem. 2013 Jan;50(Pt 1):53-61
pubmed: 23129721
Br J Gen Pract. 2016 Jul;66(648):350
pubmed: 27364658
Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211
pubmed: 24286461
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949
Aliment Pharmacol Ther. 2020 Apr;51(7):689-698
pubmed: 32048751
Inflamm Bowel Dis. 2020 Sep 18;26(10):1562-1571
pubmed: 32105310
J Clin Med. 2020 Aug 20;9(9):
pubmed: 32825383
Dig Dis Sci. 2008 Jan;53(1):47-51
pubmed: 17468955
Intern Med J. 2019 Jan;49(1):94-100
pubmed: 29962008
J Clin Lab Anal. 2016 Sep;30(5):500-5
pubmed: 26879689
Clin Chem Lab Med. 2018 Oct 25;56(11):1926-1935
pubmed: 29729144
Clin Lab. 2017 May 1;63(5):907-913
pubmed: 28627817
J Crohns Colitis. 2015 Jan;9(1):26-32
pubmed: 25008478
Can J Gastroenterol Hepatol. 2017;2017:1450970
pubmed: 28491862
J Crohns Colitis. 2013 Dec;7(12):e641-51
pubmed: 23810085
Gastroenterology. 2005 May;128(5):1172-8
pubmed: 15887101
Int J Colorectal Dis. 2009 Jan;24(1):49-55
pubmed: 18941760
Ann Clin Biochem. 2010 May;47(Pt 3):259-63
pubmed: 19740914
Scand J Gastroenterol. 2016;51(2):211-7
pubmed: 26359672
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):436-9
pubmed: 22411269
Liver Int. 2011 Oct;31(9):1406-15
pubmed: 22093455
Clin Biochem. 2012 May;45(7-8):552-5
pubmed: 22056737
Clin Chem Lab Med. 2017 Aug 28;55(10):1564-1573
pubmed: 28222018
Inflamm Bowel Dis. 2016 Feb;22(2):336-44
pubmed: 26535869
Inflamm Bowel Dis. 2015 May;21(5):1072-6
pubmed: 25793326
Int J Obes (Lond). 2013 Feb;37(2):317-9
pubmed: 22410961
J Clin Pathol. 2018 Apr;71(4):316-322
pubmed: 28844038
Inflamm Bowel Dis. 2010 Jul;16(7):1091-2
pubmed: 19834972
Am J Gastroenterol. 2015 Jun;110(6):881-7
pubmed: 25916224
Clin Chem Lab Med. 2017 Aug 28;55(9):1435-1446
pubmed: 28076305
PLoS One. 2017 Sep 21;12(9):e0185131
pubmed: 28934315
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Clin Chem Lab Med. 2008;46(9):1275-80
pubmed: 18597588
Gastroenterology. 2021 Mar;160(4):1118-1130.e3
pubmed: 33307026
Inflamm Bowel Dis. 2018 Mar 19;24(4):839-848
pubmed: 29506137
Ann Clin Biochem. 2012 Jan;49(Pt 1):55-8
pubmed: 21930735
J Crohns Colitis. 2019 Oct 28;13(11):1372-1379
pubmed: 30944925
Arq Gastroenterol. 2015 Jan-Mar;52(1):50-4
pubmed: 26017083
Clin Lab. 2016 Jul 01;62(7):1249-1254
pubmed: 28164652
J Crohns Colitis. 2013 Dec;7(12):982-1018
pubmed: 24184171
Intest Res. 2018 Oct;16(4):546-553
pubmed: 30301339
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1742-1749.e2
pubmed: 28606846
Gastroenterology. 2000 Jul;119(1):15-22
pubmed: 10889150
Aliment Pharmacol Ther. 2010 Jan 15;31(2):323-30
pubmed: 19817723
J Crohns Colitis. 2020 Feb 10;14(2):254-266
pubmed: 31403666
Dig Liver Dis. 2017 Sep;49(9):991-996
pubmed: 28587751
Int J Mol Med. 2018 Jan;41(1):107-118
pubmed: 29115397
World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):127-130
pubmed: 28533922
Gut. 2001 Sep;49(3):402-8
pubmed: 11511563
Clin Chim Acta. 2016 May 1;456:1-6
pubmed: 26908083
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1929-36.e1
pubmed: 26051392
World J Gastroenterol. 2018 Sep 7;24(33):3681-3694
pubmed: 30197475
Clin Gastroenterol Hepatol. 2014 Nov;12(11):1865-70
pubmed: 24993368
Dig Dis Sci. 2018 Mar;63(3):610-618
pubmed: 29332165
Eur J Gastroenterol Hepatol. 2003 May;15(5):573-4; author reply 574
pubmed: 12702920
Scand J Gastroenterol. 2009;44(8):939-46
pubmed: 19504404
Clin Chim Acta. 2017 Oct;473:124-126
pubmed: 28847684
J Clin Gastroenterol. 2018 Mar;52(3):235-240
pubmed: 28009684
Int J Colorectal Dis. 2008 Oct;23(10):985-92
pubmed: 18629518
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):279-84
pubmed: 14973103